
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+7
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the bodys immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
Targeted c3 therapies,complement system,hematology,ophthalmology,nephrology,paroxysmal nocturnal hemoglobinuria (pnh),geographic atrophy (ga),c3 glomerulopathy (c3g),cold agglutinin disease (cad),gene therapy,neurology,and amyotrophic lateral sclerosis (als)
Apellis pharmaceuticals operates in the Biotechnology research industry.
Apellis pharmaceuticals's revenue is 501m - 1b
Apellis pharmaceuticals has 501 - 1000 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.